VACCITECH PLC(NASDAQ:VACC) stock News

VACC Latest News, Press Relases and Analysis

All

Press Releases

2 years ago - By: Barinthus Biotherapeutics - Mentions: BRNS

Vaccitech Renames as Barinthus Biotherapeutics to Highlight Strategic Evolution into a T Cell Immunotherapy Company Targeting Chronic Infectious Diseases, Autoimmunity, and Cancer

2 years ago - By: Benzinga - Mentions: BWV NRBO ONTX DRIO ...

12 Health Care Stocks Moving In Tuesday's After-Market Session

2 years ago - By: InvestorPlace - Mentions: PRZO MTEK VINO CELZ ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

2 years ago - By: Benzinga - Mentions: FRES ICPT SLNO NVOS ...

12 Health Care Stocks Moving In Tuesday's Intraday Session

2 years ago - By: Vaccitech plc

Vaccitech to Host KOL Webinar on Seeking a Functional Cure for Chronic Hepatitis B on September 20, 2023

2 years ago - By: Vaccitech plc

Vaccitech to Host KOL Webinar on Seeking a Functional Cure for Chronic Hepatitis B on September 20, 2023

2 years ago - By: Vaccitech plc

Vaccitech Reports Second Quarter 2023 Financial Results and Recent Corporate Developments

2 years ago - By: Vaccitech plc

Vaccitech Reports Second Quarter 2023 Financial Results and Recent Corporate Developments

2 years ago - By: Vaccitech plc

Vaccitech to Present Positive Final Data at EASL Congress for Phase 1b/2 HBV002 Study in Adults with Chronic Hepatitis B

2 years ago - By: Vaccitech plc

Vaccitech to Present Positive Final Data at EASL Congress for Phase 1b/2 HBV002 Study in Adults with Chronic Hepatitis B

2 years ago - By: Arbutus Biopharma Corporation - Mentions: ABUS

Arbutus Doses First Patient in Additional Treatment Arm of Phase 2a Triple Combination Clinical Trial that Includes a PD-1 Monoclonal Antibody

2 years ago - By: Vaccitech plc

Vaccitech Doses First Patient in PCA001, a Prostate Cancer Phase 1/2 Clinical Trial of VTP-850 Immunotherapeutic Candidate in Men with Rising PSA after Definitive Local Therapy

2 years ago - By: Vaccitech plc

Vaccitech Doses First Patient in PCA001, a Prostate Cancer Phase 1/2 Clinical Trial of VTP-850 Immunotherapeutic Candidate in Men with Rising PSA after Definitive Local Therapy

2 years ago - By: Vaccitech plc

Vaccitech Reports First Quarter 2023 Financial Results and Recent Corporate Developments

3 years ago - By: InvestorPlace - Mentions: KNSA PNT VIR OCUP ...

7 Thrilling Biotech Stocks for Aggressive Investors to Buy

3 years ago - By: Vaccitech plc

Vaccitech Announces Positive Topline Final Data for HBV002 Study in People with Chronic Hepatitis B

3 years ago - By: Vaccitech plc

VACCITECH PLC (VACC) Stock News

VACC Latest News, Press Relases and Analysis

Vaccitech Renames as Barinthus Biotherapeutics to Highlight Strategic Evolution into a T Cell Immunotherapy Company Targeting Chronic Infectious Diseases, Autoimmunity, and Cancer

12 Health Care Stocks Moving In Tuesday's After-Market Session

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

12 Health Care Stocks Moving In Tuesday's Intraday Session

Vaccitech to Host KOL Webinar on Seeking a Functional Cure for Chronic Hepatitis B on September 20, 2023

Vaccitech to Host KOL Webinar on Seeking a Functional Cure for Chronic Hepatitis B on September 20, 2023

Vaccitech Reports Second Quarter 2023 Financial Results and Recent Corporate Developments

Vaccitech Reports Second Quarter 2023 Financial Results and Recent Corporate Developments

Vaccitech to Present Positive Final Data at EASL Congress for Phase 1b/2 HBV002 Study in Adults with Chronic Hepatitis B

Vaccitech to Present Positive Final Data at EASL Congress for Phase 1b/2 HBV002 Study in Adults with Chronic Hepatitis B

Arbutus Doses First Patient in Additional Treatment Arm of Phase 2a Triple Combination Clinical Trial that Includes a PD-1 Monoclonal Antibody

Vaccitech Doses First Patient in PCA001, a Prostate Cancer Phase 1/2 Clinical Trial of VTP-850 Immunotherapeutic Candidate in Men with Rising PSA after Definitive Local Therapy

Vaccitech Doses First Patient in PCA001, a Prostate Cancer Phase 1/2 Clinical Trial of VTP-850 Immunotherapeutic Candidate in Men with Rising PSA after Definitive Local Therapy

Vaccitech Reports First Quarter 2023 Financial Results and Recent Corporate Developments

7 Thrilling Biotech Stocks for Aggressive Investors to Buy

Vaccitech Announces Positive Topline Final Data for HBV002 Study in People with Chronic Hepatitis B

Vaccitech Reports Full-Year 2022 Financial Results and an Update on Corporate Developments